Current status and future prospects of transforming growth factor‐β as a potential prognostic and therapeutic target in the treatment of breast cancer

The transforming growth factor‐β (TGF‐β) signaling pathway is one of the important pathways involved in the cancer cell proliferation, invasion, migration, angiogenesis, apoptosis, as well as in metastasis by agitation or invasion of metastasis‐related factors, including matrix metalloproteinase (MM...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular biochemistry 2019-05, Vol.120 (5), p.6962-6971
Main Authors: Amerizadeh, Forouzan, Bahrami, Afsane, Khazaei, Majid, Hesari, AmirReza, Rezayi, Majid, Talebian, Sahar, Maftouh, Mona, Moetamani‐Ahmadi, Mehrdad, Seifi, Sima, Shahidsales, Soodabeh, Joudi‐Mashhad, Mona, Ferns, Gordon A., Ghasemi, Faezeh, Avan, Amir
Format: Article
Language:English
Subjects:
Angiogenesis
Antisense oligonucleotides
Apoptosis
Breast cancer
Cancer
Cell adhesion
Cell adhesion & migration
Cell adhesion molecules
Cell migration
Cell proliferation
Data processing
Growth factors
Matrix metalloproteinase
Mesenchyme
Metalloproteinase
Metastases
Metastasis
Monoclonal antibodies
Oligonucleotides
Pharmacology
prognostic biomarker
Signal transduction
Signaling
Stem cells
Therapeutic applications
Transforming growth factor-b
transforming growth factor‐β
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The transforming growth factor‐β (TGF‐β) signaling pathway is one of the important pathways involved in the cancer cell proliferation, invasion, migration, angiogenesis, apoptosis, as well as in metastasis by agitation or invasion of metastasis‐related factors, including matrix metalloproteinase (MMP), epithelial‐to‐mesenchymal transition (EMT), tumor microenvironment (TME), cancer stem cells (CSCs), and cell adhesion molecules (CAMs). These data suggest its potential value as a therapeutic object in the treatment of malignancies including breast cancer. Several pharmacological approaches have been established to suppress TGF‐β pathway; such as vaccines, small molecular inhibitors, antisense oligonucleotides, and monoclonal antibodies. Some of these are now approved by the US Food and Drug Administration for targeting the TGF‐β signaling pathway. This study attempts to summarize the current data about the functions of TGF‐β in cancer cells, and their probable application in the cancer therapy with a specific emphasis on recent preclinical and clinical research in the treatment of breast cancer and its prognostic value.
ISSN:0730-2312
1097-4644
DOI:10.1002/jcb.27831